NCT07805954Phase 3Recruiting

Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mutated Pancreatic Adenocarcinoma

Study sponsor: Revolution Medicines, Inc. · RVMD

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2029-03Estimated
Enrollment · participants400Estimated
Source updated2026-11-06Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.